Exabis Library
Welcome to the e-CCO Library!
DOP79: Dose escalation of upadacitinib in Crohn’s Disease patients with inadequate response: Data from the randomised CELEST study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP79: Effect of vedolizumab on surgical rates in IBD: post hoc analysis from the GEMINI trials
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP79: Effect of vedolizumab on surgical rates in IBD: Post hoc analysis from the GEMINI trials
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP79: Primary hypogammaglobulinemia with IBD-like features: An ECCO CONFER Multicenter Case Series
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP79: Promising efficacy of biologicals and small molecules for microscopic colitis: results from a large real-life multicenter cohort
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP80 Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: A multi-centre comparative study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP80: Automatic detection of ulcers and erosions in PillCam™ Crohn’s capsule using a convolutional neural network
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP80: Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s Disease refractory to anti-tumor necrosis factor: A multi-center comparative study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP80: Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s Disease refractory to anti-tumor necrosis factor: A multi-center comparative study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP80: Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition with ritlecitinib (PF-06651600) in Ulcerative Colitis (UC) (Phase 2b Vibrato study)
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP80: Multi-omic sequencing reveals distinctive gene expression and DNA methylation alterations as potential predictors of primary sclerosing cholangitis development in treatment-naïve paediatric ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP80: Multi-omic sequencing reveals distinctive gene expression and DNA methylation alterations as potential predictors of primary sclerosing cholangitis development in treatment-naïve paediatric ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP80: Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn's disease treated with concomitant thiopurines: the POPCUR trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP80: Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn's disease treated with concomitant thiopurines: the POPCUR trial.
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP80: Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP81 Time to loss of efficacy among patients in remission following induction treatment with tofacitinib 10 mg BID who reduced tofacitinib dose or discontinued tofacitinib in OCTAVE sustain
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP81: Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn’s Disease in the SERENE studies
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP81: Quality improvement by semi-automated benchmarking of a core outcome quality indicator set in Inflammatory Bowel Disease: A multicentric feasibility study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP81: Rosnilimab, a novel PD-1 agonist monoclonal antibody, reduces T cell proliferation, inflammatory cytokine secretion, and PD-1high expressing CD4 and CD8 T cells: Results from a Phase 1 healthy volunteer clinical trial
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP81: Time to loss of efficacy among patients in remission following induction treatment with tofacitinib 10 mg BID who reduced tofacitinib dose or discontinued tofacitinib in OCTAVE Sustain
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM